Trial Profile
Phase I/II study of inhaled doxorubicin plus IV docetaxel and cisplatin in patients with locally advanced or metastatic unresectable non small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jul 2007
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zivena
- 19 Aug 2005 New trial record.